¿¬¹ø |
ÀϽà |
°»ç¸í |
°¿¬Á¦¸ñ |
1 |
2019.1.17. |
2018³âµµ ¼Ò±Ô¸ð¿¬±¸È¸ ¹ßǥȸ - 1Â÷ |
³»ºÐºñ´ë»ç³»°ú
Á¶³Èñ ±³¼ö |
sodium glucose cotransporter-2 ¾ïÁ¦Á¦ Ä¡·á¿¡ µû¸¥ orexin-A level
ÀÇ º¯È |
½Å°æ°ú
±èÇö¾Æ ±³¼ö |
Çѱ¹ÀÎÀÇ facial flushingÀÇ À¯º´À²°ú ÀÓ»ó¾ç»ó, ¿øÀΰú Ä¡·á°æ°ú ¿¬±¸ |
½ÅÀå³»°ú
¹éÁøÇõ ±³¼ö |
½ÅÀåÀÌ½Ä È¯ÀÚ Ä¡·áÀÇ ÇÐÁ¦°£ ¿¬±¸ |
½ÉÀå³»°ú
±èÀÎö ±³¼ö |
½ÉÀåÀÌ½Ä ÈÄ °ÅºÎ¹ÝÀÀÀ» Á¤È®È÷ ¿¹ÃøÇϰí Áø´ÜÇÏ´Â ¹æ¹ýÀ» ¿¬±¸ |
¾Ë·¹¸£±â³»°ú
Á¤Ã¢±Ô ±³¼ö |
ÁÖ»ç¿ë Á¶¿µÁ¦ °ú¹Î¹ÝÀÀ¿¡ ´ëÇÑ °ü¸®¿Í ¿¹¹æ |
À§Àå°ü¿Ü°ú
·ù½Â¿Ï ±³¼ö |
°æÀ念¾ç ½Ã ºñÀ§°ü°ú À§·ç°üÀÇ È¿¿ë¼º ºñ±³ |
ÈäºÎ¿Ü°ú
¹Ú³²Èñ ±³¼ö |
½ÉÀå ÀçȰÇÁ·Î±×·¥ÀÇ °³¹ß ¹× Àû¿ë |
2 |
2019.1.31. |
2018³âµµ ¼Ò±Ô¸ð¿¬±¸È¸ ¹ßǥȸ - 2Â÷ |
·ù¸¶Æ¼½º³»°ú
äÁø³ç ±³¼ö |
·ù¸¶Æ¼½º°üÀý¿° Ȱ¸·¼¼Æ÷¿¡¼ new cox-2 inhibitor ÀÇ È°¸·¼¼Æ÷ »ç¸ê
¹× ÀÚ°¡Æ÷½Ä¿¡ ¹ÌÄ¡´Â °ü°è±Ô¸í |
º´¸®°ú
Á¤Çý¶ó ±³¼ö |
ºñ´¢±â°è¾ÏÀÇ º´Å»ý¸® |
ºñ´¢±â°ú
Á¤¿øÈ£ ±³¼ö |
Clinical implication of spot urine analysis of calcium and uric acid in urinary calculus patients |
¼Ò¾ÆÃ»¼Ò³â°ú
¹ÚÀçÇö ±³¼ö |
Comparison of urinary Neutrophil Gelatinase-associated Lipocalin/Cr ratio, serum Cystatin C and Creatinine according to postnatal age in very low birth weight infants(VLBWIs) |
½ÉÀå³»°ú
Çã½ÂÈ£ ±³¼ö |
°¡»óÇö½Ç°ú Áõ°Çö½ÇÀ» ÀÌ¿ëÇÑ °ÔÀÓÇü ½ÉÀåÀçȰ ±â±¸°³¹ß¿¬±¸ |
½ÉÀå³»°ú
ÇѼº¿í ±³¼ö |
PHM(Prognostics & Health Management) Á¢¸ñ°¡´ÉÇÑ ÀÇ·á±â±âÀÇ
±â¼ú°³¹ß |
½Å°æ°ú
¼®Èï¿ ±³¼ö |
Ç÷´ç º¯µ¿Æø¿¡ µû¸¥ ´ç´¢º´¼º ÀÚÀ²½Å°æº´ÁõÀÇ ÁøÇà Á¤µµ |
½Å°æ¿Ü°ú
ÀÌ⿵ ±³¼ö |
³úÇ÷°üÁúȯÀÇ Áø´Ü, Ä¡·áÀÇ ÃֽŠÁö°ß°ú ÀÌ¿Í °ü·ÃµÈ ¿µ»óÁø´Ü±â±â ¹×
Ä¡·á±â±¸ÀÇ R&D¸¦ À§ÇÑ ´ÙÇÐÁ¦Àû Á¢±ÙÀ» ÅëÇÑ ´Ù¾çÇÑ ¿¬±¸ |
3 |
2019.2.14. |
2018³âµµ ¼Ò±Ô¸ð¿¬±¸È¸ ¹ßǥȸ - 3Â÷ |
½Å°æ°ú
±è±ÙÅ ±³¼ö |
24½Ã°£ ºñµð¿À - ³úÆÄ °Ë»ç ±â¹ÝÀÇ ³úÀüÁõ Áø´Ü ¹× Ä¡·á±â¼ú°³¹ß |
´ëÀåÇ×¹®¿Ü°ú
¹è¼º¿í ±³¼ö |
´ëÀå¾Ï ȯÀÚ¿¡ ÀÖ¾î¼ ´ë»çȰ¼ºÁ¾¾çºÎÇÇ¿Í ÃѺ¯º¯ÇØ´ç°¡ ¿¹ÈÄ¿¡
¹ÌÄ¡´Â ¿µÇâ |
·ù¸¶Æ¼½º³»°ú
¼Õâ³² ±³¼ö |
Åëdz ¹× ¿©·¯ ¿°Áõ¼º °üÀý¿° ȯÀڵ鿡¼ caspase-1ÀÇ ÀÓ»óÀû ÀÇ¹Ì |
º´¸®°ú
±Ç¼±¿µ ±³¼ö |
Æó°æ ÈÄ À¯¹æ¾Ï ȯÀÚÀÇ ÀÓ»ó°æ°ú¿¡ Áö¹æºÐÆ÷°¡ ¹ÌÄ¡´Â ¿µÇâ |
Á¤Çü¿Ü°ú
À̰æ¶ô ±³¼ö |
µ¿°á°ßÀÇ Ä¡·áÁ¦·Î¼ ºñŸ¹Î DÈ¿°ú ±Ô¸í - ÀÎü ¹× µ¿¹° ¸ðµ¨ ¿¬±¸ |
ÇǺΰú
·ù¿µ¿í ±³¼ö |
ÇǺμ¶À¯¾Æ¼¼Æ÷, °¢Áú Çü¼º¼¼Æ÷¿¡¼ UVB-induced senescence
Çö»ó°ú ÀÌ·Î ÀÎÇÑ ÇǺΠ±¤³ëÈ¿¡ °ü¿©ÇÏ´Â ±âÀü°ú ÀÎÀÚ¿¡ ´ëÇÑ ¿¬±¸ |
ÈäºÎ¿Ü°ú
±èÀçÇö ±³¼ö |
À¯Àü¼º ´ëµ¿¸ÆÁúȯ ¿¬±¸ ¹× °ü·Ã À¯ÀüÀÚ Registry ±¸Ãà Áغñ |
ÇÙÀÇÇаú
±èÇØ¿ø ±³¼ö |
³úÇ÷°üÁúȯ°ú ÅðÇ༺ ³úÁúȯÀÇ »ó°ü°ü°è ±Ô¸í |
¿¬¹ø |
°ú Á¦ ¸í |
¿¬±¸Ã¥ÀÓÀÚ |
ÃÑ ¿¬±¸±â°£ |
ÃÑ¿¬±¸ºñ(¿ø) |
1 |
ÀÚ±â ÁÖµµÇü ÈÞ´ë¿ë »ýȰȯ°æ
¾ÈÀüÁø´Ü ŰƮ ¾Û±â¹Ý ¼ºñ½º ½Ã½ºÅÛ |
½ÉÀå³»°ú |
Á¶À±°æ |
2016.5.1.~
2020.4.30. |
4³â |
685,000,000 |
2 |
3Â÷¿ø ½ÉÀå ¸ÅÇÎ ½Ã½ºÅÛ ¹× Ç÷°ü
°¡½ÃÈ ±â¼ú ±â¹Ý Áö´ÉÇü ½ÉÇ÷°ü ÁßÀç
½Ã¼ú º¸Á¶ ·Îº¿ ½Ã½ºÅÛ °³¹ß |
½ÉÀå³»°ú |
¹ÚÇü¼· |
2017.4.1.~
2021.12.31. |
3³â
9°³¿ù |
337,500,000 |
4 |
AR ±â¼ú Àû¿ë ½ÉÇ÷°ü°è ½Ã¼ú
°¡»óÈÆ·Ã ½Ã¹Ä·¹ÀÌÅÍ °³¹ß |
½ÉÀå³»°ú |
ÇѼº¿í |
2017.12.20.~
2020.11.30. |
2³â
11°³¿ù |
523,000,000 |
5 |
À¯Ã¼µ¿¿ªÇÐ À¯Ã¼Ä¨ ±â¹Ý °£¾Ï
Áø´Ü±â±â °³¹ß |
¼Òȱ⳻°ú |
À庴±¹ |
2016.4.1.~
2019.3.31. |
3³â |
33,500,000 |
6 |
mTORC2 network Á¦¾î¸¦ ÅëÇÑ
¼¼Æ÷»ç¸ê switch ÅëÇÕÁ¶Àý ¿¬±¸ |
¸é¿ªÇÐ |
¹Î°æÁø |
2016.11.1.~
2019.10.31. |
3³â |
150,000,000 |
7 |
ºñ¾ËÄݼº Áö¹æ°£ÀÌ µ¿¹ÝµÈ Á¤»ó
½Å±â´É ´ç´¢º´È¯ÀÚ¿¡¼
¼Òº¯¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¿ªÇÒ |
³»ºÐºñ³»°ú |
ÇÑÀ¯Áø |
2017.11.01.~
2019.10.31. |
2³â |
20,000,000 |
8 |
¾È¸éºÎ Áö¹æ À̽ļú¿¡¼
±âÁúÇ÷°üºÐȹ¼¼Æ÷ (SVF)
µ¿½ÃÀ̽ļúÀÇ À¯È¿¼º Æò°¡¸¦ À§ÇÑ
ÀüÇâÀû ¹«ÀÛÀ§ ´ëÁ¶ÀÓ»ó½ÃÇè |
¼ºÇü¿Ü°ú |
±èÁØÇü |
2018.4.30.~
2020.12.31. |
2³â
8°³¿ù |
186,250,000 |
9 |
¸¸¼º ½ÉºÎÀü ȯÀÚ °ü¸®¸¦ À§ÇÑ »ðÀÔÇü
ÇÇÇÏ »ýüÁ¶Á÷ÀúÇ× ÃøÁ¤±â±â °³¹ß |
½ÉÀå³»°ú |
±èÀÎö |
2018.4.30.~
2020.12.31. |
2³â
8°³¿ù |
295,000,000 |
10 |
´ÙÁßÁø´ÜĨ ±â¹Ý ´ç´¢º´ ¹×
´ç´¢º´ÇÕº´Áõ ÀÌÇà¿¹Ãø ¸ðµ¨ °³¹ß |
³»ºÐºñ´ë»ç
³»°ú |
Á¶È£Âù |
2018.7.26.~
2026.12.31. |
8³â
5°³¿ù |
6,871,000,000 |
11 |
´ç´¢º´¼º ±Ë¾çÀÇ Àç»ý ÀÎÀÚ¿¡ °üÇÑ
¿¬±¸ |
ÇǺΰú |
±è¼º¾Ö |
2018.12.10.~
2019.12.9. |
1³â |
20,000,000 |